Innate Pharma présente ses résultats financiers et l’avancée de son portefeuille au premier semestre 2021

by NASDAQ Market News September 15, 2021

NASDAQ Market News
Click here to email author

Pulmocide’s lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA

Avalo Therapeutics, Inc. Announces Pricing of $27.5 Million Public Offering of Common Stock

Ads